Moxisylyte API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Moxisylyte API

Moxisylyte, also known as Thymoxamine, is a synthetic pharmaceutical compound belonging to the alpha-1 adrenergic receptor antagonist class. It has been investigated and used in pharmaceutical applications involving vascular smooth-muscle relaxation and urological disorders.

Moxisylyte acts by blocking alpha-1 adrenergic receptors, which can reduce adrenergic-mediated vasoconstriction and promote relaxation of vascular smooth muscle. It has historically been used in the management of conditions including erectile dysfunction and Raynaud's disease, depending on its pharmaceutical form and market.

Moxisylyte free base has the molecular formula C₁₆H₂₅NO₃, molecular weight 279.3746 g/mol, and is an achiral compound with no optical activity.

About Moxisylyte API

Moxisylyte is a substituted phenoxyethyl dimethylamine derivative with alpha-adrenergic blocking activity. It has been marketed or investigated in different pharmaceutical applications, including urological use.

The hydrochloride salt, Moxisylyte Hydrochloride, is a separately identified pharmaceutical substance with CAS 964-52-3 and molecular weight approximately 315.83 g/mol.

Key Features

  • Active Pharmaceutical Ingredient
  • Alpha-1 adrenergic antagonist
  • Alpha-adrenergic blocking agent
  • Also known as Thymoxamine
  • Free-base CAS Number: 54-32-0
  • Molecular Formula: C₁₆H₂₅NO₃
  • Molecular Weight: 279.37 g/mol
  • Achiral compound
  • No optical activity
  • Pharmaceutical applications in vascular and urological research
  • Available as the hydrochloride salt for pharmaceutical applications
  • Suitable for pharmaceutical research, development and manufacturing subject to applicable regulatory requirements

PHARMACEUTICAL APPLICATIONS

Moxisylyte has been used as an alpha-adrenergic blocking agent.

Historical pharmaceutical applications include:

  • Erectile dysfunction
  • Raynaud's disease
  • Vascular smooth-muscle relaxation
  • Urological pharmaceutical research
  • Research involving alpha-1 adrenergic receptor antagonism

NCATS identifies moxisylyte as an alpha-1 adrenergic antagonist and reports its historical use in erectile dysfunction.

For your commercial API page, avoid presenting every historical or investigational application as a currently approved indication worldwide.

MECHANISM OF ACTION

Moxisylyte acts primarily as an alpha-1 adrenergic receptor antagonist.

Alpha-1 adrenergic receptors participate in vasoconstriction and contraction of vascular smooth muscle. By blocking these receptors, moxisylyte reduces alpha-adrenergic-mediated smooth-muscle contraction and promotes vasodilation.

This pharmacological activity forms the basis for its historical applications in vascular and urological conditions.

Detailed Specifications

Parameter Specification
Appearance White crystalline powder or crystals
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Heavy Metals NMT 20 ppm
Individual Impurity NMT 0.5%
Total Impurities NMT 2.0%
Water Content NMT 1.0%
Get Bulk Quote via WhatsApp